DTech Liquidating

DTech Liquidating Profit per Employee

Delisted

The Profit per Employee of DTech Liquidating (DMTKQ) as of Oct 20, 2026 is -362,906.47 USD. In the previous year, Profit per Employee was -419,712.23 USD — a change of -13.53% (higher).

Profit per Employee

-362,906.47USD

YoY

-13.53%

Last updated:

Profit per Employee of DTech Liquidating is 2023 -362,906.47 USD. Profit per Employee of DTech Liquidating was 2022 -419,712.23 USD. It decreases by -13.53% higher compared to the previous year.

The DTech Liquidating Profit per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Profit per Employee
Date
Profit per Employee
Jan 1, 2017
-827.34 USD
Jan 1, 2018
2,661.87 USD
Jan 1, 2019
-70,827.34 USD
Jan 1, 2020
-131,223.02 USD
Jan 1, 2021
-281,798.56 USD
Jan 1, 2022
-419,712.23 USD
Jan 1, 2023
-362,906.47 USD
The DTech Liquidating Profit per Employee history
YEARProfit per EmployeeYoY
-362,906.47USD-13.53%
-419,712.23USD+48.94%
-281,798.56USD+114.75%
-131,223.02USD+85.27%
-70,827.34USD-2,760.81%
2,661.87USD-421.74%
-827.34USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DTech Liquidating Stock analysis

What does DTech Liquidating do? DTech Liquidating Inc, trading under the ticker DMTKQ with ISIN US24984K1051, is a U.S.-based company headquartered in San Diego. It operates within the Health Care sector, specifically in the Biotechnology industry. The company has 278 employees and completed its IPO on June 20, 2017. DTech Liquidating Inc is focused on the development and sale of products for the diagnosis and treatment of skin diseases. Its technology involves non-invasive genomics tests designed to aid in the diagnosis and management of skin cancer, inflammatory skin diseases, and aging-related skin conditions. The company utilizes a method that detects genomic markers associated with melanoma through non-invasive skin sample collection, aiming to identify higher-risk lesions at early stages to rule out melanoma. The DermTech Melanoma Test, also known as the DMT or Pigmented Lesion Assay (PLA), is marketed for the clinical assessment of pigmented skin lesions that may indicate melanoma. The company's products are intended to address unmet needs in the diagnostic process for pigmented skin lesions, commonly referred to as moles. DTech Liquidating Inc's operations are centered around providing innovative solutions for skin disease diagnosis and management, leveraging non-invasive genomic analysis techniques. DTech Liquidating is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DTech Liquidating stock

Profit per Employee of DTech Liquidating is -362,906.47 USD in 2023.

Profit per Employee of DTech Liquidating changed from -419,712.23 USD to -362,906.47 USD, representing a -13.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Profit per Employee DTech Liquidating since 2006 – with annual values, charts, and detailed analysis.

Profit per employee measures how much net income each employee generates on average. It is a key indicator of workforce efficiency.

Profit per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Profit per Employee's DTech Liquidating historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — DTech Liquidating

All Key Metrics — DTech Liquidating